Rezolute, Inc.
RZLTHealthcare|Biotechnology|US
$3.88
+0.24 (+6.59%)
DCF Value
$0.05
Tangible Book / Share
$0.82
Cash / Share
$0.86
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06208215 RZ358 Treatment for Congenital Hyperinsulinism | Congenital Hyperinsulinism | P3 | Active | 56 | RCT, Double-blind | RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC |
| NCT06881992 A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | Tumor Hyperinsulinism (Tumor HI) | P3 | Recruiting | 16 | Open-label | Ersodetug |
| NCT05712720 Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME) | Diabetic Macular Edema | P2 | Completed | 94 | RCT, Double-blind | Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402 |
| NCT04538989 An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism | Congenital Hyperinsulinism | P2 | Completed | 23 | Open-label | RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4 |
| NCT07262970 Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor | Tumor-associated Hyperinsulinism (Tumor HI) | AVAILABLE | — | — | Ersodetug (9 mg/kg) + SOC |